Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could one blood thinner be enough after a heart attack? new trial aims to find out

NCT ID NCT07583784

Disease control Sponsor: Chonnam National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 03, 2026 · Updated 4 times

Summary

This study compares two approaches to blood thinning after a heart attack in patients with atrial fibrillation. One group gets two blood thinners (a DOAC plus clopidogrel), while the other gets only one (a DOAC alone). The goal is to see if using just one drug reduces bleeding risks without increasing the chance of another heart attack or stroke. About 860 adults will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Direct oral anticoagulants (apixaban, edoxaban, or rivaroxaban) with or without clopidogrel
What this could lead to
If successful, this could show that using only one blood thinner is safer and just as effective as two after a heart attack in people with atrial fibrillation, potentially reducing bleeding complications.
What could go wrong
This is a relatively early-stage trial with 860 participants, and the results may not apply to all patients. There is a risk that single therapy might not prevent future heart attacks or strokes as well as dual therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 860 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Dec 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients aged 19 years old 2. Patients with AF and CHA2DS2-VA score ≥2. 3. ST-segment elevation myocardial infarction (STEMI) or Non-ST-segment elevation myocardial infarction (NSTEMI) * STEMI: ST-segment elevation ≥0.1 mV in ≥2 contiguous leads or documented newly developed left bundle-branch block.12 * NSTEMI: NSTEMI is defined as a combination of criteria with mandated elevation of a cardiac biomarker, preferably high-sensitive cardiac troponin with at least one value above 99th percentile of the upper reference limit and at least one of the following:12 1. Symptoms of ischemia. 2. New or presumed new significant ST-T wave changes 3. Development of pathological Q waves on electrocardiography. 4. Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality. 5. Intracoronary thrombus detected on angiography. 4. Patients underwent PCI for AMI (STEMI or NSTEMI) at least 6 months before enrollment. Exclusion Criteria: 1. Patients contraindicated for use of DOACs or clopidogrel 2. Mechanical prosthetic valve or moderate-to-severe mitral stenosis requiring vitamin K antagonist 3. Planned cardiac surgery within 1 year after randomization 4. Patients with severe thrombocytopenia or coagulopathy 5. Liver cirrhosis or severe hepatic dysfunction 6. Advanced chronic kidney disease (creatinine clearance \<15 ml/min/1.73 m2) or on dialysis 7. Prior history of intracranial hemorrhage 8. Coexisting conditions related to high risk of life-threatening bleeding 9. Pregnancy or breast feeding 10. Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment) 11. Unwillingness or inability to comply with the procedures described in this protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Af - atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction atrial fibrillation myocardial infarction Non-ST Elevated Myocardial Infarction ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Af - atrial fibrillation Myocardial infarction (MI) Nstemi - non-ST-segment elevation myocardial infarction ST-segment elevation myocardial infarction (stemi)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chonnam National University Hospital

    RECRUITING

    Gwangju, Gwangju, 61469, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.